User:M. Louie, UCSF/sandbox


 * 1) Add a citation for any topic: In a randomized, multicentered, double blind, placebo controlled trial, using Palivizumab for RSV prophylaxis resulted in 55% reduction in hospitalization events.

Mechanism of Action:

Palivizumab is a monoclonal antibody that targets the fusion (F) glycoprotein on the surface of RSV, and deactivates it. The F protein is a membrane protein responsible for fusing the virus with its target cell and is highly conserved among subgroups of RSV. Deactivating the F protein prevents the virus from fusing with its target's cell membrane and keeps the cell safe from infection.

Potential edits:

- clean up 2014 guideline wording

- production/history

- summarize costs + differences in opinion over use due to cost between some reviews + 2014 AAP guidelines.

- Anaphylaxis reports to side effects